Skip to main content

Table 4 Influence of CDKN2 deletion by different TKI treatments

From: Correlation between deletion of the CDKN2 gene and tyrosine kinase inhibitor resistance in adult Philadelphia chromosome-positive acute lymphoblastic leukemia

  Imatinib (n = 26) Dasatinib (n = 18) P value
CR after induction 22/26 (84.6 %) 17/18 (94.4 %) 0.634
CMR after induction 2/23 (8.7 %) 4/16 (25.0 %) 0.205
Transplantation 19/26 (73.1 %) 15/18 (83.3 %) 0.489
Relapse 16/26 (61.5 %) 10/18 (55.6 %) 0.691
OS (median time) 16.5 (1.2–38.7) 18.4 (3–41.9) 0.508
DFS (median time) 12.9 (0–37.7) 14.2 (0–41) 0.555
  1. CR complete remission, Allo-HSCT allogeneic hematopoietic stem cell transplantation, DFS disease-free survival, OS overall survival